2020 AASLD Abstract Categories and Descriptors (The Liver Meeting®)

**Acute Liver Failure and Artificial Liver Support**
AO1  Acute Liver Failure and Artificial Liver Support

**Advanced Practice Providers (NP, PA, RN, PharmD, etc.)**
BO1  Behavioral and Quality Issues
BO2  Practice Issues

**Alcohol-associated Liver Diseases: Clinical and Experimental**
CO1  Alcohol-associated Liver Diseases: Clinical and Experimental

**Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis**
DO1  Transport, Bilirubin, Cholesterol, Lipids, and Bile Salts
DO2  Cholangiocyte Biology
DO3  Experimental Cholestasis

**Cell and Molecular Biology**
EO1  Cell Structure and Function
EO2  Signal Transduction and Nuclear Receptors
EO3  Gene Expression and Therapy
EO4  Stem Cell Biology

**Genomics and Precision Medicine**
FO1  Genomics and Precision Medicine

**Gut Liver Axis and Microbiome**
GO1  Gut Liver Axis and Microbiome

**Health Services and Public Health Research**
HO1  Health Care Delivery/Access/Quality/Equity
HO2  Cost-Effectiveness and Economics of Care
HO3  Patient Centered Outcomes Research

**Hepatitis B**
IO1  Virology, Pathogenesis, and Immunology
IO2  Diagnostics and Biomarkers
IO3  Epidemiology, Prevention, Natural History
IO4  Therapeutics: Approved Agents
IO5  Therapeutics: New Agents

**Hepatitis C**
JO1  Virology, Pathogenesis, and Immunology
JO2  Diagnostics, Epidemiology, and Natural History
JO3  Therapeutics: New Agents
JO4  Therapies: General Populations
JO5  Therapies: Unique Populations

**Hepatitis: Other Infections**
KO1  Hepatitis: Other Infections
**Hepatobiliary Neoplasia**
- LO1 Experimental Hepatocarcinogenesis
- LO2 Diagnostics and Liver Imaging
- LO3 Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma

**Hepatotoxicity**
- MO1 Pathogenesis and Mechanisms
- MO2 Drug Metabolism, Toxicity and Therapeutics
- MO3 Predictors of Drug Toxicity

**Human Cholestatic and Autoimmune Liver Diseases**
- NO1 PBC/PSC and Other Cholestatic Disease
- NO2 Autoimmune Liver Disease

**Inflammation and Immunobiology**
- OO1 Animal Models
- OO2 Innate Immunity
- OO3 Adaptive Immunity
- OO4 Mechanisms of Injury

**Liver Fibrogenesis and Non-Parenchymal Cell Biology**
- PO1 Basic Fibrosis Research and Stellate Cell Biology
- PO2 Imaging and Noninvasive Markers of Liver Disease
- PO3 Clinical and Translational Fibrosis Research

**Liver Transplantation and Liver Surgery**
- QO1 Cellular Immunobiology, Preservation, and Cell Transplantation
- QO2 Donor and Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery
- QO3 Immunosuppression, Outcomes, Complications
- QO4 Viral Hepatitis

**Metabolic and Genetic Disease**
- RO1 Hemochromatosis, Wilson Disease, and α-1 Antitrypsin Deficiency

**NAFLD and NASH**
- SO1 Experimental: Basic
- SO2 Experimental: Clinical
- SO3 Epidemiology and Natural History, Prevention and Outcomes
- SO4 Diagnostics and Biomarkers
- SO5 Therapeutics: Pharmacologic and Other

**Pediatric Hepatology**
- TO1 Pediatric Liver Disease – Basic Science
- TO2 Biliary Atresia and Cholestasis
- TO3 Viral and Autoimmune Hepatitis
- TO4 Metabolic and Genetic Diseases
- TO5 Pediatric Liver Transplantation
Portal Hypertension and Other Complications of Cirrhosis
UO1 Experimental
UO2 Ascites, Renal Dysfunction, and Hepatorenal Syndrome
UO3 Varices and Bleeding
UO4 Encephalopathy and Other Complications
UO5 Infections and Acute on Chronic Liver Failure

Training and Education (Career Development)
VO1 Training and Education (Career Development)

COVID-19 and the Liver
1. Basic
2. Clinical/Translational
3. Transplant
4. Health Services